Stoke Therapeutics, Inc.
STOK
NASDAQ·Healthcare·Biotechnology·Mkt cap $1.9B
$29.81
▼ -0.60%
P/E
-8.87
Mkt Cap
$1.9B
52-Wk Range
$20.32–$40.22
52-Week Range
$20.32 - $40.22
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 35.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary TANGO RNA technology
- Targeted antisense oligonucleotide platform
- Focus on rare genetic neurological disorders
- Strategic collaboration with Acadia Pharmaceuticals
Bear Case
1 risk
- Average volatility.
Growth
Moderate growth ahead
Advancing clinical trials for STK-001
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Stable
+2.8% over 3m
Quality
Excellent
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying STOK right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 3, 2026
AUG 3, 2026
Reported EPS of -$0.93 vs -$0.80 consensus (-17.0% surprise). Revenue of $9.3M vs $4.9M expected (+90.7%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-17.0%
Revenue trend · last 8Q
—
+707%
—
+186%
+117%
-94%
-96%
-33%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$4.9M
$22.6M
$158.6M
$13.8M
$10.6M
$1.4M
$6.2M
$9.3M
Margins · last 8Q
Gross
0.0%
Operating
—
Profit
-660.8%
Wall Street consensus
6 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Goldman Sachs · Jul 13, 2026
vs Industry
How STOK stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related